On Wednesday, OHR Pharmaceutical Inc (NASDAQ:OHRP)’s shares declined -7.84% to $2.82.
Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development company declared that Jason S. Slakter, MD, has been designated Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the Company’s sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the Company’s board of directors.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
At the end of Wednesday’s trade, Perrigo Company plc Ordinary Shares (NYSE:PRGO)‘s shares dipped -0.52% to $189.65.
Perrigo Company plc (PRGO) declared that it has reached a contract to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is predictable to generate about €30 million in full year 2015 net sales. Yokebe, the second largest dietary brand (by market share) in Germany, comes in a shake/liquid form and is marketed within the ‘meal replacement’ category.
The acquisition is predictable to be right away accretive to Perrigo’s calendar 2015 adjusted earnings per share and to exceed Perrigo’s ROIC threshold in calendar year 2016. The transaction has been unanimously approved by the Boards of Directors of Perrigo and Naturwohl Pharma, and is predictable to close in the third quarter, pending German regulatory approval and the satisfaction of customary closing conditions.
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, in addition to in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), ended its Wednesday’s trading session with 2.23% gain, and closed at $7.81.
BioDelivery Sciences International, Inc. (BDSI) declared that it will report its second quarter ended June 30, 2015 financial results and host a conference call and webcast on Monday, August 10, 2015.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain administration and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which comprises of a small, bi-layered erodible polymer film for application to the buccal mucosa.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
